专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

51. 发明申请

US20130156792A9 Uniform field magnetization and targeting of therapeutic formulations 有权
公开(公告)号：US20130156792A9
公开(公告)日：2013-06-20
申请号：US12653465
申请日：2009-12-15
申请人： Robert J. Levy , Michael Chorny , Vladimir Muzykantov , Elizabeth Hood
发明人： Robert J. Levy , Michael Chorny , Vladimir Muzykantov , Elizabeth Hood
IPC分类号： A61K39/44 , A61F2/82 , C12N13/00 , A61K38/44 , A61P43/00 , A61N2/10 , A61M31/00
CPC分类号： A61K9/5094 , A61K9/5115 , A61K9/5123 , A61K9/5146 , A61K9/5153 , A61K9/5169 , A61K9/5192 , A61K47/42 , A61K47/59 , A61K47/645 , A61K47/6455 , A61K47/6849 , A61K47/6921 , A61K47/6937 , A61K48/0008 , A61K48/0041 , A61K48/0083 , A61L31/16 , A61L2300/416 , A61L2300/60 , A61L2300/624 , C12N15/111 , C12N15/86 , C12N2320/32 , C12N2710/10343
摘要： Systems and methods for magnetic targeting of therapeutic particles are provided. Therapeutic particles comprise one or more magnetic or magnetizable materials and at least one therapeutic agent. Therapeutic particles are specifically targeted using uniform magnetic fields capable of magnetizing magnetizable materials, and can be targeted to particular locations in the body, or can be targeted for capture, containment, and removal. Therapeutic particles can comprise antioxidant enzymes, and can be targeted to cells to protect the cells from oxidative damage.

52. 发明申请

US20090068745A1 COMPOSITIONS AND METHODS FOR PERFORMING REVERSE GENE THERAPY 审中-公开
标题翻译：用于进行逆转基因治疗的组合物和方法
公开(公告)号：US20090068745A1
公开(公告)日：2009-03-12
申请号：US11872664
申请日：2007-10-15
申请人： Robert J. Levy , Denise Y. Burton
发明人： Robert J. Levy , Denise Y. Burton
IPC分类号： C12N15/87 , C12N15/09 , C12N15/79
CPC分类号： A61K9/1647 , A61K9/5153 , A61K31/7048 , A61K38/177 , A61K48/00 , A61K48/0025 , A61K48/0041 , A61K48/005
摘要： The invention relates to compositions and methods for reverse gene therapy, wherein a gene therapy vector encoding a gene product (e.g. a protein) which is usually only expressed in cells of an abnormal tissue is delivered to a cell of an animal afflicted with a disease or disorder to alleviate the disease or disorder. In one embodiment, a plasmid vector encoding HERG (A561V) protein is delivered to a cell of an animal afflicted with re-entrant atrial flutter-mediated cardiac arrhythmia.
摘要翻译：本发明涉及用于逆基因治疗的组合物和方法，其中编码通常仅在异常组织的细胞中表达的基因产物（例如蛋白质）的基因治疗载体被递送至患有疾病的动物的细胞或紊乱以缓解疾病或病症。在一个实施方案中，将编码HERG（A561V）蛋白质的质粒载体递送至患有再入院心房扑动介导的心律失常的动物的细胞。

53. 发明授权

US06852704B1 Reverse gene therapy 有权
标题翻译：反向基因治疗
公开(公告)号：US06852704B1
公开(公告)日：2005-02-08
申请号：US09487851
申请日：2000-01-19
申请人： Robert J. Levy , Scott Baldwin
发明人： Robert J. Levy , Scott Baldwin
IPC分类号： A01N63/00 , A61K9/16 , A61K9/51 , A61K35/00 , A61K48/00 , C07H21/04 , C12N1/20 , C12N15/00 , C12N15/63 , C12N15/74 , C12N15/85 , C12N15/86 , C12P21/06
CPC分类号： A61K9/5153 , A61K9/1647 , A61K48/0041 , A61K48/005
摘要： The invention relates to compositions and methods for reverse gene therapy, wherein a gene therapy vector encoding a gene product (e.g. a protein) which is usually only expressed in cells of an abnormal tissue is delivered to a cell of an animal afflicted with a disease or disorder to alleviate the disease or disorder. In one embodiment, a plasmid vector encoding HERG (A561V) protein is delivered to a cell of an animal afflicted with re-entrant atrial flutter-mediated cardiac arrhythmia.
摘要翻译：本发明涉及用于逆基因治疗的组合物和方法，其中编码通常仅在异常组织的细胞中表达的基因产物（例如蛋白质）的基因治疗载体被递送至患有疾病的动物的细胞或紊乱以缓解疾病或病症。在一个实施方案中，将编码HERG（A561V）蛋白质的质粒载体递送至患有再入院心房扑动介导的心律失常的动物的细胞。

54. 发明授权

US06333194B1 Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof 有权
标题翻译：用于控制传播病毒载体的水凝胶组合物及其使用方法
公开(公告)号：US06333194B1
公开(公告)日：2001-12-25
申请号：US09487854
申请日：2000-01-19
申请人： Robert J. Levy , Timothy Crombleholme , Narendra Vyavahare
发明人： Robert J. Levy , Timothy Crombleholme , Narendra Vyavahare
IPC分类号： C12N1563
CPC分类号： A61K47/42 , A61K47/6903 , Y10S977/80
摘要： The invention relates to compositions and methods for delivering a virus vector to an animal. The compositions include compositions which comprise a hydrogel matrix (e.g. a collagen matrix which can comprise a poloxamer or an alginate) containing a virus vector therein in a transfectious form. The invention also includes methods of making such hydrogel precursor mixtures and hydrogel matrices, including particles, devices, bulk materials, and other objects which comprise, consist of, or are coated with such mixtures or matrices. The invention further relates to compositions comprising a hydrogel precursor mixture having a virus vector suspended therein, which, when administered to an animal, gel to form a hydrogel matrix containing a virus vector therein in a transfectious form. Methods of delivering a virus vector to an animal tissue are also described.
摘要翻译：本发明涉及将病毒载体递送至动物的组合物和方法。组合物包括包含其中以转染形式含有病毒载体的水凝胶基质（例如可包含泊洛沙姆或藻酸盐的胶原基质）的组合物。本发明还包括制备这样的水凝胶前体混合物和水凝胶基质的方法，包括颗粒，装置，散装材料和其它物体，其包含，组成或被这些混合物或基质涂覆。本发明还涉及包含其中悬浮有病毒载体的水凝胶前体混合物的组合物，当将其施用于动物时，凝胶以转染形式形成含有病毒载体的水凝胶基质。还描述了将病毒载体递送到动物组织的方法。

55. 发明授权

US5674298A Calcification-resistant bioprosthetic tissue and methods of making same 失效
标题翻译：抗钙化生物假体组织及其制备方法
公开(公告)号：US5674298A
公开(公告)日：1997-10-07
申请号：US478287
申请日：1995-06-07
申请人： Robert J. Levy , Eyal Lerner
发明人： Robert J. Levy , Eyal Lerner
IPC分类号： A61L27/00 , A61F2/24 , A61L27/36 , A61L27/50 , A61F2/02
CPC分类号： A61L27/3687 , A61L27/50 , A61L2400/02 , A61L2430/40 , Y10S623/921
摘要： Naturally-derived bioprosthetic materials are treated with epoxide crosslinking agents. In some embodiments, the tissue is crosslinked with low molecular weight epoxides in aqueous solutions at high pH levels. In other embodiments, the tissue is crosslinked at physiologic pH levels with epoxide crosslinking agents catalyzed with tertiary or quaternary amines, such as Tris or imidazole. In an advantageous embodiment, bioprosthetic tissue is crosslinked and derivatized with an anticalcification agent, such as a polyphosphonate anticalcification agent, using a polyphosphonate:polyepoxide monoadduct.
摘要翻译：天然来源的生物纤维材料用环氧化物交联剂处理。在一些实施方案中，组织在高pH值水溶液中与低分子量环氧化物交联。在其他实施方案中，组织在生理pH水平下与用叔胺或季胺如Tris或咪唑催化的环氧化物交联剂交联。在有利的实施方案中，使用聚膦酸盐：聚环氧化物单加成物，用抗再钙剂如多膦酸盐抗角化剂将生物假体组织进行交联和衍生化。

56. 发明授权

US4343734A Protein diagnostic for atherosclerosis 失效
标题翻译：蛋白质诊断动脉粥样硬化
公开(公告)号：US4343734A
公开(公告)日：1982-08-10
申请号：US111115
申请日：1980-01-10
申请人： Jane B. Lian , Robert J. Levy , Paul M. Gallop
发明人： Jane B. Lian , Robert J. Levy , Paul M. Gallop
IPC分类号： A61K35/44 , A61K39/00 , G01N33/531 , A61K35/14 , A61K37/02 , A61K49/02 , C07G7/00
CPC分类号： A61K35/44 , G01N33/531 , A61K39/00 , Y10S530/829 , Y10S530/841
摘要： Compositions and processes featuring, in one aspect, a process of purifying a protein diagnostic for atherosclerosis comprising separating out of primate and human atherosclerotic tissue a Gla-containing protein of molecular weight of about 80,000.
摘要翻译：组合物和方法在一个方面特征在于提供一种纯化动脉粥样硬化蛋白质诊断的方法，其中包括从灵长类动物和人类动脉粥样硬化组织中分离出约80,000分子量的含Gla蛋白质。

57. 发明申请

US20130018454A1 Small Diameter Vascular Graft Produced by a Hybrid Method 有权
公开(公告)号：US20130018454A1
公开(公告)日：2013-01-17
申请号：US13511511
申请日：2010-11-24
申请人： Peter I. Lelkes , Mengyan Li , Anat Perets , Pimporn Uttayarat , Robert J. Levy , Russell J. Composto
发明人： Peter I. Lelkes , Mengyan Li , Anat Perets , Pimporn Uttayarat , Robert J. Levy , Russell J. Composto
IPC分类号： A61F2/04 , A61F2/06 , B05D5/00
CPC分类号： A61F2/0077 , A61F2/06 , A61F2/062 , A61F2002/0081 , A61F2002/0086 , A61F2240/001 , A61F2310/00005 , A61F2310/00389 , A61L27/18 , A61L27/3808 , A61L27/3813 , A61L27/3817 , A61L27/3821 , A61L27/507 , A61L2430/32 , D01D5/0076 , D01F6/70 , D10B2331/041 , D10B2509/06 , C08L67/04
摘要： The present invention relates to a hybrid graft and methods of generating the hybrid graft. The hybrid graft comprises an exterior surface and a luminal surface. The luminal surface comprises a micropattern of grooves to which cells adhere and orient along. The exterior surface comprises electrospun microfibers wherein the microfibers provide mechanical properties to the graft. The hybrid graft is capable supporting endothelial cell attachment, endothelial cell alignment, cell proliferation, and maintaining their in vivo function. The graft of the invention can recapitulate the in vivo morphology and function of natural vascular endothelium.

58. 发明申请

US20120251586A1 LIGAND-SPECIFIC INHIBITION OF ATTACHMENT OF IMMUNE CELLS TO IMPLANTABLE BIOMATERIALS 审中-公开
标题翻译：将免疫细胞连接到可植入生物材料的特异性抑制
公开(公告)号：US20120251586A1
公开(公告)日：2012-10-04
申请号：US13262367
申请日：2010-04-09
申请人： Stanley J. Stachelek , Dennis Discher , Robert J. Levy , Richard Tsai
发明人： Stanley J. Stachelek , Dennis Discher , Robert J. Levy , Richard Tsai
IPC分类号： A61L31/10 , C08G18/83 , A61M25/00 , A61K39/395 , A61K9/00 , A61N1/05 , C08F8/00 , A61K38/17
CPC分类号： A61L31/10 , A61L27/34 , A61L27/54 , A61L31/022 , A61L31/048 , A61L33/128 , A61L2300/252 , A61L2300/432 , A61L2300/606 , A61L2300/802 , C08L89/00
摘要： Methods for protecting biomaterials comprise attaching CD47 or Ig domain thereof to the surface of the biomaterial, thereby inhibiting or reducing immune cell attachment and/or immune cell-mediated damage to the biomaterial. Also provided are kits for practicing these methods and the protected biomaterials.
摘要翻译：用于保护生物材料的方法包括将CD47或Ig结构域连接到生物材料的表面，从而抑制或减少对生物材料的免疫细胞附着和/或免疫细胞介导的损伤。还提供了用于实施这些方法和受保护的生物材料的试剂盒。

59. 发明授权

US07282489B2 Compositions and methods for performing reverse gene therapy 有权
标题翻译：用于进行逆基因治疗的组合物和方法
公开(公告)号：US07282489B2
公开(公告)日：2007-10-16
申请号：US10422551
申请日：2003-07-31
申请人： Robert J. Levy , Denise Y. Burton
发明人： Robert J. Levy , Denise Y. Burton
IPC分类号： A61K48/00
CPC分类号： A61K9/1647 , A61K9/5153 , A61K31/7048 , A61K38/177 , A61K48/00 , A61K48/0025 , A61K48/0041 , A61K48/005
摘要： The invention relates to compositions and methods for reverse gene therapy, wherein a gene therapy vector encoding a gene product (e.g. a protein) which is usually only expressed in cells of an abnormal tissue is delivered to a cell of an animal afflicted with a disease or disorder to alleviate the disease or disorder. In one embodiment, a plasmid vector encoding HERG (A561V) protein is delivered to a cell of an animal afflicted with re-entrant atrial flutter-mediated cardiac arrhythmia.
摘要翻译：本发明涉及用于逆基因治疗的组合物和方法，其中编码通常仅在异常组织的细胞中表达的基因产物（例如蛋白质）的基因治疗载体被递送至患有疾病的动物的细胞或紊乱以缓解疾病或病症。在一个实施方案中，将编码HERG（A561V）蛋白质的质粒载体递送至患有再入院心房扑动介导的心律失常的动物的细胞。

60. 发明授权

US5436291A Calcification-resistant synthetic biomaterials 失效
标题翻译：抗钙合成生物材料
公开(公告)号：US5436291A
公开(公告)日：1995-07-25
申请号：US181742
申请日：1994-01-21
申请人： Robert J. Levy , Ravi Joshi
发明人： Robert J. Levy , Ravi Joshi
IPC分类号： A61L27/00 , A61L27/14 , A61L27/18 , A61L27/36 , A61L27/50 , A61L33/00 , C08G18/38 , C08G59/14 , C08K5/5353 , C08L27/06 , C08L27/18 , C08L75/04 , C08L101/00 , C08L101/02 , C08G18/10
CPC分类号： C08K5/5353 , A61L27/14 , A61L27/18 , A61L27/50 , A61L27/54 , A61L33/0011 , C08G59/1488 , A61L2400/02
摘要： Synthetic biomaterials are provided with irreversibly bound amino diphosphonate, polyphosphonate, or other anticalcification agent to prevent in vivo calcification. Such biomaterials include biocompatible elastomers such as polyurethane and/or polydimethylsiloxane, and the like which are intended for invasive, or in-dwelling use in a human or animal body. Illustratively, reaction conditions utilizing hi-or polyfunctional epoxides result in epoxide bridge incorporation of the anticalcification agent to the biomaterial elastomer.
摘要翻译：提供合成生物材料具有不可逆结合的氨基二膦酸盐，聚膦酸盐或其它抗细胞剂以防止体内钙化。这样的生物材料包括生物相容性弹性体，例如聚氨酯和/或聚二甲基硅氧烷等，其旨在用于人或动物体内的侵入性或住宅用途。说明性地，使用高或多官能环氧化物的反应条件导致抗氧化剂向生物材料弹性体中引入环氧化物桥。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式